Research News
A MOTS-c analogue has a first-in-human record. Efficacy is still thin.
CB4211, an analogue of the mitochondrial peptide MOTS-c, was taken into a phase 1 study in people with obesity and type 2 diabetes. The registry, not a product page, is the source.
MOTS-c entered the literature as a mitochondrial-encoded peptide in a 2015 Cell Metabolism paper, in mouse models of diet and insulin resistance. Years later, an analogue called CB4211 was registered for a first-in-human phase 1a/1b study in people with obesity and type 2 diabetes. The registry identifier is NCT04004273. That registration is the fact worth reporting. A completed animal paper does not silently become a human efficacy result.
What phase 1 is for
Phase 1 asks whether a dose can be given and what happens to safety signals, pharmacokinetics, and early laboratory measures. Public topline discussion of CB4211 has been limited. Limited means readers should not upgrade a safety-oriented study into a claim about weight, glucose, or healthy aging. If a sponsor posts results, they belong on the registry record and in a paper, where the endpoints were pre-specified.
Two different molecules
The mouse peptide and the clinical analogue are related and not interchangeable. Catalog vials sold as MOTS-c are a third thing again: a research-supply product outside both the 2015 experiment and NCT04004273. This note stops at the registry. It does not point at a shop.